TherapeuticsMD (TXMD) Misses Q1 EPS by 2c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St set for higher open as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
TherapeuticsMD Announces First Quarter 2020 Financial Results
May 6, 2020 6:50 AM EDT- 1Q20 total net product revenue of $12.3 million exceeded Wall Street consensus -
- Significantly reducing operating expenses, while maintaining goal of achieving EBITDA breakeven in 2021 -
- In discussions with TPG Sixth Street Partners to defer the scheduled start of quarterly revenue covenants due to COVID-19 -
- First Orange Book listed patent for ANNOVERA® issued providing potential extended exclusivity to 2039 -
- Strengthened board of directors with diverse industry veterans -
- Conference call scheduled for... More
